8-K
filed August 2, 2023, 7:59 PM ET
ticker SPNT
CIK 0001576018
earnings
confidence high
sentiment positive
materiality 0.75
SiriusPoint Q2 net income $66M, core combined ratio 87.7%, targeting double-digit ROE in 2023
SiriusPoint Ltd
2023-Q2 EPS reported
$1.14
revenue$1,453,000,000
- Q2 2023 net income available to common shareholders $66M, $0.37 per diluted share; H1 net income $205M.
- Core combined ratio 87.7% for Q2, 84.4% for H1; consolidated combined ratio 81.9% (Q2) and 78.2% (H1).
- Net investment income $69M in Q2, $130M in H1; FY2023 guidance reaffirmed at $220-240M.
- Run-rate cost savings of $35-40M vs prior year on underlying basis; targeting >$50M by end 2024.
- Quarterly cash dividend of $0.50 per Series B preference share declared, payable Aug 31, 2023.
Key facts
Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
SiriusPoint Ltd reported the second quarter ended June 30, 2023 results: net income $66 million, EPS $0.37 per diluted common share. Guidance reaffirmed.
- Period
- the second quarter ended June 30, 2023
- Net income
- $66 million
- EPS
- $0.37 per diluted common share
- Guidance
- reaffirmed
- Result
- reported results
Exact text from the filing
Net income available to SiriusPoint common shareholders of $66 million, or $0.37 per diluted common share
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
SiriusPoint Ltd reported the six months ended June 30, 2023 results: net income $205 million, EPS $1.14 per diluted common share. Guidance reaffirmed.
- Period
- the six months ended June 30, 2023
- Net income
- $205 million
- EPS
- $1.14 per diluted common share
- Guidance
- reaffirmed
- Result
- reported results
Exact text from the filing
Net income available to SiriusPoint common shareholders of $205 million, or $1.14 per diluted common share
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.